Medical Dermatology Therapy Update is organized by Cleveland Clinic Center for Continuing Education and will be held from Sep 03 - 05, 2020 at Global Center For Health Innovation, Cleveland, Ohio, United States of America.
Who Should Attend?
This course is designed for physicians and advanced practice clinicians in dermatology, immunology, oncology, rheumatology, internal medicine, family medicine, and general practice.
The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Live activity, Medical Dermatology Therapy Update, with a beginning date of 04/29/2020, has been reviewed and is acceptable for up to 18.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.25 MOC points in the american Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Dermatology MOC
This activity offers 25 ABD MOC self-assessment credits approved by the american Board of Dermatology (ABD). Successful completion of the online selfassessment enables the participant to earn 25 ABD MOC self-assessment credits, in addition to any AMA PRA Category 1 Credit™ claimed for the live event. To receive ABD MOC, pre-registration is required.
Attend this CME-certified educational activity for a unique opportunity to update your knowledge and understanding of both traditional and new therapeutic strategies for a range of critically important medical dermatologic conditions, including rheumatology-dermatology overlap diseases, atopic dermatitis, advanced melanoma and other cutaneous malignancies, urticaria, sarcoidosis, hidradenitis suppurativa, autoimmune bullous disease, cutaneous lymphomas, alopecia areata, and psoriatic disease.
By attending, you will be able to:
• Describe recent advances in biologic and small-molecule inhibitor drug development for immune-mediated and malignant dermatologic diseases.
• Describe updates in traditional treatment options, both skin-directed and systemic, for medical dermatologic diseases.
• Summarize updates in the pathogenesis of various medical dermatologic diseases and how this relates to both drug development and use of traditional and modern therapeutic options.
• Illustrate ocular, pulmonary, oral, and articular manifestations that may be found in patients with rheumatologic-dermatologic overlap diseases.
• Critically appraise the safety and efficacy of various adjunct therapeutic strategies for patients taking biologic or small molecule inhibitor medications.
• Review the current knowledge of the impact of systemic treatment for moderate-to-severe psoriasis on future cardiovascular health.
• Summarize the importance of an interprofessional team approach for optimal care of patients with complex medical dermatologic diseases, and provide examples of effective team workflows.
|Contact No. :||216.444.9990,
|Registration Type||Last Date||Price|
|Physician - Early Fee||03 Aug,2020||USD 375.00|
|Non-Physician - Early Fee||03 Aug,2020||USD 250.00|
|Resident/Fellow - Early Fee||03 Aug,2020||USD 0.00|
|Corporate - Early Fee||03 Aug,2020||USD 500.00|
Plan Your Travel
Reviews Given by People
Hotels Near Venue
Subscribe to our Newsletterx
Subscribe to our newsletter and receive updates on medical conferences, board review courses and news